In short
Brukinsa for the treatment of adult patients with Marginal Zone Lymphoma (MZL) who have received at least one prior anti-CD20 based therapy, and for whom there are no available clinical studies have been approved by the FAMHP (Federal Agency for Medicines and Health Products) on May 23rd.
More detailed information can be found at Brukinsa l FAMHP or can be requested via email to beigene.belux@beigene.com.
Information sheet
Member login required
This content is part of our learning materials for our members. Login or see our membership information